Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia (NCT04994717)
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)
🩺 Plain-English Summary (8th-Grade Level)
The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab alternating with low-intensity chemotherapy to EFS and (OS) of participants receiving standard of care (SOC) chemotherapy.
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 40 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (192 Sites)
Showing the first 25 of 192 sites.
- City of Hope National Medical Center — Duarte, California
- University of California Irvine — Orange, California
- University of California San Francisco — San Francisco, California
- Adventist Health System/Sunbelt, Inc d/b/a AdventHealth Orlando — Orlando, Florida
- Cleveland Clinic Foundation — Cleveland, Ohio
- Saint Francis Hospital, Inc — Greenville, South Carolina
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Canberra Hospital — Garran, Australian Capital Territory
- Royal Prince Alfred Hospital — Camperdown, New South Wales
- Liverpool Hospital — Liverpool, New South Wales
- Royal North Shore Hospital — St Leonards, New South Wales
- Westmead Hospital — Westmead, New South Wales
- Royal Brisbane and Womens Hospital — Herston, Queensland
- Princess Alexandra Hospital — Woolloongabba, Queensland
- Royal Adelaide Hospital — Adelaide, South Australia
- Monash Medical Centre — Clayton, Victoria
- Austin Health, Austin Hospital — Heidelberg, Victoria
- Peter MacCallum Cancer Centre — Melbourne, Victoria
- The Alfred Hospital — Melbourne, Victoria
- Fiona Stanley Hospital — Murdoch, Western Australia
- Medizinische Universitaet Graz — Graz,
- Medizinische Universitaet Innsbruck — Innsbruck,
- Ordensklinikum Linz Elisabethinen — Linz,
- Hanusch Krankenhaus — Vienna,
- Institut Jules Bordet — Anderlecht,
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.